Psoriasis Trends and Practice Gaps - 29/06/16
, Jacqueline E. Greb, BA, Ari M. Goldminz, MDRésumé |
The present article addresses several high-impact practice gaps affecting psoriatic patients, current practices, the barriers that prevent the delivery of optimal care, and recommendations to improve patient outcomes. Discussions of treatment, cardiovascular risk factor screening, psoriatic arthritis screening, and biologics are included. Finally, an overview of current resident exposure to psoriatic care and recommendations for improvements in resident education are made.
Le texte complet de cet article est disponible en PDF.Keywords : Psoriasis, Psoriatic arthritis, Practice gaps, Treatment trends, Biologics, Resident education
Plan
| Conflicts of Interest: A.B. Gottlieb currently has consulting/advisory board agreements with the following: Amgen Inc; Astellas, Akros, Centocor (Janssen), Inc; Celgene Corp; Bristol Myers Squibb Co; Beiersdorf, Inc; Abbott Labs (Abbvie); TEVA; Actelion; UCB; Novo Nordisk; Novartis; Dermipsor Ltd; Incyte; Pfizer; Canfite; Lilly; Coronado; Vertex; Karyopharm; CSL Behring Biotherapies for Life; Glaxo Smith Kline; Xenoport; Catabasis; Meiji Seika Pharma Co, Ltd; Takeda; and Mitsubishi Tanabe Pharma Development America, Inc. She has research/educational grants (paid to Tufts Medical Center) with the following: Centocor (Janssen), Amgen, Abbott (Abbvie), Novartis, Celgene, Pfizer, Lilly, Coronado, Levia, Merck, and Xenoport. J.E. Greb and A.M. Goldminz have no conflicts to report. |
Vol 34 - N° 3
P. 235-242 - juillet 2016 Retour au numéro
Article précédent
- Practice Gaps and Training Gaps: Delineating What We Need to Fix
- Murad Alam
- Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea
- Nicole M. Fett, David Fiorentino, Victoria P. Werth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?